Senseonics (SENS) Shares Down 7.3%

Senseonics Holdings Inc (NYSEAMERICAN:SENS) fell 7.3% during mid-day trading on Wednesday . The stock traded as low as $2.61 and last traded at $2.67. 2,033,191 shares traded hands during mid-day trading, an increase of 40% from the average session volume of 1,448,282 shares. The stock had previously closed at $2.88.

Separately, UBS Group began coverage on shares of Senseonics in a research note on Tuesday, November 27th. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $6.00.

Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.14) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.01. The business had revenue of $5.16 million for the quarter, compared to analyst estimates of $5.16 million. During the same quarter in the prior year, the firm earned ($0.13) EPS. The firm’s quarterly revenue was up 145.7% on a year-over-year basis.

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc lifted its holdings in shares of Senseonics by 8.7% during the third quarter. Vanguard Group Inc now owns 4,779,370 shares of the company’s stock valued at $22,797,000 after acquiring an additional 382,058 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Senseonics by 8.7% during the third quarter. Vanguard Group Inc. now owns 4,779,370 shares of the company’s stock valued at $22,797,000 after acquiring an additional 382,058 shares during the period. Teachers Advisors LLC lifted its holdings in shares of Senseonics by 109.8% during the third quarter. Teachers Advisors LLC now owns 268,684 shares of the company’s stock valued at $1,282,000 after acquiring an additional 140,617 shares during the period. MetLife Investment Advisors LLC lifted its holdings in shares of Senseonics by 78.1% during the third quarter. MetLife Investment Advisors LLC now owns 61,240 shares of the company’s stock valued at $292,000 after acquiring an additional 26,861 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Senseonics during the third quarter valued at $3,944,000. Hedge funds and other institutional investors own 30.66% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/11/senseonics-sens-shares-down-7-3.html.

About Senseonics (NYSEAMERICAN:SENS)

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Further Reading: What is Compound Interest?

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply